$
6.170
+0.91(17.300%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.420
Open
5.760
VWAP
--
Vol
3.62M
Mkt Cap
16.51M
Low
5.3101
Amount
--
EV/EBITDA(TTM)
--
Total Shares
27.97M
EV
-39.35M
EV/OCF(TTM)
--
P/S(TTM)
--
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Show More
3 Analyst Rating
up Image
45.87% Upside
Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 9.00 USD with a low forecast of 3.00 USD and a high forecast of 15.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
up Image
45.87% Upside
Current: 6.170
sliders
Low
3.00
Averages
9.00
High
15.00
Piper Sandler
Edward Tenthoff
Overweight
downgrade
$36 -> $15
2025-07-15
Reason
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on NextCure to $15 from $36 and keeps an Overweight rating on the shares. The firm notes NextCure exercised a 12-for-1 reverse stock split effective July 14th. Piper estimates NextCure now has 2.338 million shares outstanding and trades at an $11.5M market cap.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$3
2025-03-17
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$4 → $3
2025-03-07
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$8 → $4
2024-11-11
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$4
2024-08-02
Reason

Valuation Metrics

The current forward P/E ratio for NextCure Inc (NXTC.O) is -0.32, compared to its 5-year average forward P/E of -1.64. For a more detailed relative valuation and DCF analysis to assess NextCure Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.64
Current PE
-0.32
Overvalued PE
-0.31
Undervalued PE
-2.98

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.15
Undervalued EV/EBITDA
-0.07

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-30.29%
-10.99M
Operating Profit
FY2025Q1
YoY :
-35.84%
-10.98M
Net Income after Tax
FY2025Q1
YoY :
-36.07%
-0.39
EPS - Diluted
FY2025Q1
YoY :
+2.78%
-12.99M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
882.4K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

NXTC News & Events

Events Timeline

2025-07-24 (ET)
2025-07-24
18:07:39
NextCure presents new preclinical data on osteogenesis imperfecta treatment
select
2025-06-16 (ET)
2025-06-16
07:17:58
NextCure, Simcere Zaiming announce strategic partnership
select
2025-05-01 (ET)
2025-05-01
16:39:56
NextCure reports Q1 EPS (39c), consensus (40c)
select
Sign Up For More Events

News

9.0
07-25NASDAQ.COM
PinnedNextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate
4.5
07-25Benzinga
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
9.5
07-25Benzinga
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Sign Up For More News

FAQ

arrow icon

What is NextCure Inc (NXTC) stock price today?

The current price of NXTC is 6.17 USD — it has increased 17.3 % in the last trading day.

arrow icon

What is NextCure Inc (NXTC)'s business?

arrow icon

What is the price predicton of NXTC Stock?

arrow icon

What is NextCure Inc (NXTC)'s revenue for the last quarter?

arrow icon

What is NextCure Inc (NXTC)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for NextCure Inc (NXTC)'s fundamentals?

arrow icon

How many employees does NextCure Inc (NXTC). have?

arrow icon

What is NextCure Inc (NXTC) market cap?